• Treffer 4 von 13
Zurück zur Trefferliste

Immune thrombocytopenia in two unrelated Fanconi anemia patients - a mere coincidence?

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-149837
  • Thrombocytopenia and pancytopenia, occurring in patients with Fanconi anemia (FA), are interpreted either as progression to bone marrow failure or as developing myelodysplasia. On the other hand, immune thrombocytopenia (ITP) represents an acquired and often self-limiting benign hematologic disorder, associated with peripheral, immune-mediated, platelet destruction requiring different management modalities than those used in congenital bone marrow failure syndromes, including FA. Here, we describe the clinical course of two independent FAThrombocytopenia and pancytopenia, occurring in patients with Fanconi anemia (FA), are interpreted either as progression to bone marrow failure or as developing myelodysplasia. On the other hand, immune thrombocytopenia (ITP) represents an acquired and often self-limiting benign hematologic disorder, associated with peripheral, immune-mediated, platelet destruction requiring different management modalities than those used in congenital bone marrow failure syndromes, including FA. Here, we describe the clinical course of two independent FA patients with atypical – namely immune – thrombocytopenia. While in one patient belonging to complementation group FA-A, the ITP started at 17 months of age and showed a chronically persisting course with severe purpura, responding well to intravenous immunoglobulins (IVIG) and later also danazol, a synthetic androgen, the other patient (of complementation group FA-D2) had a self-limiting course that resolved after one administration of IVIG. No cytogenetic aberrations or bone marrow abnormalities other than FA-typical mild dysplasia were detected. Our data show that acute and chronic ITP may occur in FA patients and impose individual diagnostic and therapeutic challenges in this rare congenital bone marrow failure/tumor predisposition syndrome. The management and a potential context of immune pathogenesis with the underlying marrow disorder are discussed.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Anna Karastaneva, Sofia Lanz, Angela Wawer, Uta Behrends, Detlev Schindler, Ralf Dietrich, Stefan Burdach, Christian Urban, Martin Benesch, Markus G. Seidel
URN:urn:nbn:de:bvb:20-opus-149837
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Medizinische Fakultät / Institut für Humangenetik
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):Frontiers in Pediatrics
Erscheinungsjahr:2015
Band / Jahrgang:3
Heft / Ausgabe:50
Originalveröffentlichung / Quelle:Frontiers in Pediatrics 2015, 3, 50. DOI: 10.3389/fped.2015.00050
DOI:https://doi.org/10.3389/fped.2015.00050
PubMed-ID:https://pubmed.ncbi.nlm.nih.gov/PMC4459098
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Freie Schlagwort(e):DNA repair defect; Evans syndrome; FANCA; FANCD2; Fanconi anemia; bone marrow failure syndrome; danazol; immune thrombocytopenia
Datum der Freischaltung:22.01.2019
Lizenz (Deutsch):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International